Targeting IBS-C with Acacia Fiber and Probiotics: A 4-Week Clinical Evaluation

Targeting IBS-C with Acacia Fiber and Probiotics: A 4-Week Clinical Evaluation

Objective: To investigate the effects and safety of Acacia fiber and probiotic supplements in alleviating gastrointestinal complaints in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).

?

Study Design

Type: Randomized, double-blinded, placebo-controlled intervention trial

Duration: 4 weeks

Participants: Patients with IBS-C

Methods: Participants were randomly assigned to three groups, receiving either Acacia fiber, probiotic supplements, or a placebo. Changes in symptoms, treatment efficacy, and safety were measured and analyzed through questionnaires and clinical evaluations throughout the study.

Daily variation in gastrointestinal complaints during the observation and intervention period

??

Key Findings

Symptom Improvement:

Patients receiving Acacia fiber and probiotic supplements showed significant improvements in gastrointestinal symptoms, including bloating, abdominal pain, and constipation.

These improvements were more pronounced compared to the placebo group.

?

Safety and Tolerability:

Both supplements demonstrated good safety and tolerability profiles, with no serious adverse effects reported.

This indicates the feasibility of Acacia fiber and probiotics as long-term management options for IBS-C patients.

?

Mechanistic Insights

Acacia Fiber: Works by enhancing beneficial gut microbiota, thereby improving the gut microbial environment and alleviating symptoms.

Probiotics: Help balance gut flora by reducing the proliferation of harmful bacteria and improving gut function.

?

Conclusion

Acacia fiber and probiotic supplements significantly relieve gastrointestinal symptoms in IBS-C patients and have good safety and tolerability. These findings provide a scientific basis for developing new management strategies for IBS-C.

?

?

Source: "Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial"

要查看或添加评论,请登录

Wecare Probiotics Co., Ltd.的更多文章

社区洞察

其他会员也浏览了